Scientists have worked out a way of predicting how long a prostate cancer patient will continue to respond to the PARP inhibitor drug, olaparib, according to new research published in the journal Cancer Cell.

Researchers have carried out an in-depth analysis of 10,478 cancer genomes across 35 different cancer types, identifying 330 potential cancer-driving genes, 74 of which are newly associated with cancer. The findings highlight the potential to develop new, more targeted treatment options for cancer patients.

Mobile testing ‘Man Van’ can diagnose prostate cancer in at-risk groups earlier and more affordably than GPs, according to new research.